{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:05:05Z","timestamp":1780553105024,"version":"3.54.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Africa faces a projected doubling of cancer burden by 2040, yet access to radionuclide therapies remains critically limited. This systematic review quantifies the availability, accessibility, and economic feasibility of therapeutic nuclear medicine across 54 African nations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study combined a PRISMA 2020-compliant systematic literature review with secondary database analysis. A comprehensive search was conducted across PubMed\/MEDLINE, Scopus, Web of Science, and African Journals Online (January 2022\u2013March 2026). Epidemiologic and infrastructure data were additionally obtained from GLOBOCAN 2022 and the International Atomic Energy Agency (IAEA). Risk of bias was assessed using the modified Newcastle\u2013Ottawa Scale for peer-reviewed studies and the AACODS checklist for gray literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2,847 records identified, 47 studies met the inclusion criteria. I-131 therapy for thyroid cancer is available in only 28\/54 countries (51.9%), while Lu-177-PSMA for prostate cancer is available in only seven countries (13.0%). Local radiopharmaceutical production reduces therapy costs by 93%\u201396% compared with imported agents. Africa has approximately 0.18 nuclear medicine physicians per million population vs. 3.1 in Europe. The cost reduction ratio for local vs. imported Lu-177-PSMA is 1:28.3 (US$1,500\u20133,000 vs. US$42,500).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Radionuclide therapy availability in Africa is profoundly inadequate relative to disease burden. Economic modeling demonstrates that local production and regional hub models can achieve cost reductions exceeding 90%, making therapies economically feasible for resource-limited settings. Targeted investment in cyclotron infrastructure and workforce development is urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnume.2026.1825650","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:40:59Z","timestamp":1780551659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Availability, accessibility, and economic feasibility of radionuclide therapies in Africa: a systematic review and quantitative infrastructure analysis"],"prefix":"10.3389","volume":"6","author":[{"given":"Efrah Ahmed","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Bursa Uludag University Hospital","place":["Bursa, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2967\/jnumed.125.271248","article-title":"The current status of nuclear medicine in Africa","volume":"67","author":"Brink","year":"2026","journal-title":"J Nucl Med"},{"key":"B2","volume-title":"GLOBOCAN 2022: Estimated Cancer Incidence, Mortality and Prevalence Worldwide. Africa Fact Sheet","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40336-021-00468-3","article-title":"Development of nuclear medicine in Africa","volume":"10","author":"Grigoryan","year":"2022","journal-title":"Clin Transl Imaging"},{"key":"B4","volume-title":"Rays of Hope: Cancer Care for All","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0045-1812307","article-title":"Radiotheranostics in low- and middle-income countries: challenges, practice, and prospects","volume":"9","author":"Lawal","year":"2025","journal-title":"TH Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/wjnm.WJNM_56_19","article-title":"Nuclear medicine practice in Africa: a review","volume":"19","author":"Balogun","year":"2020","journal-title":"World J Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00259-024-07040-3","article-title":"Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"52","author":"Brinkmann","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0045-1807251","article-title":"Global challenges in the provision of therapy services: the IAEA perspective","volume":"24","author":"Brink","year":"2025","journal-title":"World J Nucl Med"},{"key":"B11","first-page":"103185","article-title":"Six country vignettes: strengthening radiotherapy and theranostics infrastructure","volume":"117","author":"Zubizarreta","year":"2024","journal-title":"Phys Med"},{"key":"B12","volume-title":"World Population Prospects 2024","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.3390\/cancers17213412","article-title":"Radioligand therapy in cancer management: a global perspective on challenges and opportunities","volume":"17","author":"Ninatti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e70054","DOI":"10.1002\/ird3.70054","article-title":"Integrating nuclear medicine services into health care systems in low- and middle-income countries: a review of challenges and innovations","volume":"1","author":"Ayalew","year":"2026","journal-title":"Int Rev Diagn"},{"key":"B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0124734","DOI":"10.1371\/journal.pone.0124734","article-title":"Monitoring sub-Saharan African physician migration and recruitment post-adoption of the WHO code of practice","volume":"10","author":"Tankwanchi","year":"2015","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","article-title":"Medical imaging and nuclear medicine: a lancet oncology commission","volume":"22","author":"Hricak","year":"2021","journal-title":"Lancet Oncol"},{"key":"B19","year":""},{"key":"B20","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/a-1783-8154","article-title":"Individualized treatment of differentiated thyroid cancer","volume":"61","author":"Schmidt","year":"2022","journal-title":"Nuklearmedizin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/srao.2000.6592","article-title":"Systemic radiopharmaceutical therapy of painful osteoblastic metastases","volume":"10","author":"Silberstein","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B26","first-page":"904","article-title":"The global distribution of physicians: a review of the evidence","volume":"86","author":"Donal","year":"2008","journal-title":"Bull World Health Organ"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1825650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:41:00Z","timestamp":1780551660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2026.1825650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":26,"alternative-id":["10.3389\/fnume.2026.1825650"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2026.1825650","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1825650"}}